XML 48 R35.htm IDEA: XBRL DOCUMENT
v3.22.2

REVENUES - Disaggregation of Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 6,260 | $ 6,217 | $ 12,850 | $ 12,640
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,339 | 4,233 | 8,694 | 8,493
Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,076 | 1,192 | 2,277 | 2,528
Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 844 | 792 | 1,878 | 1,619
Total product sales |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 6,138 | 6,152 | 12,672 | 12,492
Total product sales | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,254 | 4,213 | 8,582 | 8,453
Total product sales | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,042 | 1,147 | 2,216 | 2,422
Total product sales | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 842 | 792 | 1,873 | 1,617
Total HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,228 | 3,938 | 7,935 | 7,588
Total HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3,383 | 3,044 | 6,245 | 5,830
Total HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 562 | 596 | 1,112 | 1,174
Total HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 282 | 298 | 577 | 584
Biktarvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2,556 | 1,994 | 4,707 | 3,818
Biktarvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2,095 | 1,586 | 3,801 | 3,051
Biktarvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 268 | 237 | 529 | 453
Biktarvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 193 | 171 | 376 | 314
Complera/Eviplera |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 54 | 62 | 99 | 125
Complera/Eviplera | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 20 | 20 | 37 | 45
Complera/Eviplera | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 31 | 39 | 55 | 73
Complera/Eviplera | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 3 | 7 | 7
Descovy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 460 | 435 | 834 | 794
Descovy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 397 | 357 | 708 | 639
Descovy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 32 | 44 | 64 | 86
Descovy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 32 | 34 | 63 | 69
Genvoya |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 582 | 706 | 1,164 | 1,379
Genvoya | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 482 | 551 | 939 | 1,057
Genvoya | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 72 | 100 | 149 | 206
Genvoya | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 29 | 55 | 76 | 116
Odefsey |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 364 | 382 | 703 | 749
Odefsey | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 255 | 258 | 487 | 498
Odefsey | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 97 | 111 | 193 | 224
Odefsey | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 12 | 13 | 23 | 27
Stribild |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 33 | 51 | 66 | 97
Stribild | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 24 | 35 | 46 | 66
Stribild | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 8 | 11 | 16 | 22
Stribild | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2 | 5 | 5 | 9
Truvada |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 34 | 108 | 72 | 243
Truvada | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 24 | 94 | 52 | 213
Truvada | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 6 | 9 | 13
Truvada | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 8 | 11 | 17
Revenue share - Symtuza |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 126 | 129 | 258 | 264
Revenue share - Symtuza | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 80 | 86 | 166 | 175
Revenue share - Symtuza | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 42 | 40 | 86 | 84
Revenue share - Symtuza | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4 | 3 | 6 | 5
Other HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 18 | 71 | 33 | 119
Other HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 57 | 10 | 86
Other HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 9 | 8 | 13 | 13
Other HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4 | 6 | 9 | 20
Veklury |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 445 | 829 | 1,980 | 2,285
Veklury | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 41 | 416 | 843 | 1,236
Veklury | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 126 | 264 | 430 | 652
Veklury | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 278 | 149 | 708 | 397
Total HCV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 448 | 549 | 847 | 1,059
Total HCV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 263 | 327 | 462 | 585
Total HCV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 94 | 93 | 189 | 228
Total HCV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 91 | 129 | 196 | 246
Ledipasvir/Sofosbuvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 23 | 62 | 58 | 118
Ledipasvir/Sofosbuvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 6 | 30 | 19 | 49
Ledipasvir/Sofosbuvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4 | 3 | 8 | 19
Ledipasvir/Sofosbuvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 13 | 29 | 31 | 50
Sofosbuvir/Velpatasvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 376 | 442 | 706 | 823
Sofosbuvir/Velpatasvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 227 | 262 | 389 | 476
Sofosbuvir/Velpatasvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 75 | 82 | 157 | 157
Sofosbuvir/Velpatasvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 74 | 98 | 159 | 190
Other HCV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 49 | 45 | 83 | 118
Other HCV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 30 | 35 | 54 | 60
Other HCV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 16 | 8 | 24 | 52
Other HCV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 2 | 5 | 6
Total HBV/HDV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 234 | 237 | 470 | 457
Total HBV/HDV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 100 | 90 | 180 | 171
Total HBV/HDV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 30 | 24 | 57 | 47
Total HBV/HDV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 104 | 123 | 232 | 239
Vemlidy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 195 | 200 | 394 | 381
Vemlidy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 97 | 86 | 177 | 163
Vemlidy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 9 | 8 | 18 | 16
Vemlidy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 89 | 106 | 199 | 202
Viread |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 24 | 28 | 47 | 59
Viread | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 3 | 3 | 7
Viread | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 6 | 8 | 12 | 15
Viread | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 15 | 17 | 32 | 37
Other HBV/HBD |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 16 | 9 | 28 | 17
Other HBV/HBD | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 1 | 0 | 1
Other HBV/HBD | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 15 | 8 | 28 | 16
Other HBV/HBD | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Total cell therapy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 368 | 219 | 642 | 410
Total cell therapy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 246 | 140 | 418 | 259
Total cell therapy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 105 | 70 | 197 | 135
Total cell therapy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 17 | 9 | 27 | 16
Tecartus |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 73 | 41 | 136 | 72
Tecartus | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 53 | 32 | 100 | 59
Tecartus | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 20 | 9 | 35 | 13
Tecartus | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 1 | 0
Yescarta |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 295 | 178 | 506 | 338
Yescarta | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 193 | 108 | 318 | 200
Yescarta | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 85 | 61 | 162 | 122
Yescarta | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 17 | 9 | 26 | 16
Trodelvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 159 | 89 | 305 | 161
Trodelvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 120 | 89 | 240 | 161
Trodelvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 35 | 0 | 61 | 0
Trodelvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 0 | 5 | 0
Total other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 256 | 291 | 493 | 532
Total other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 101 | 107 | 195 | 211
Total other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 88 | 100 | 169 | 186
Total other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 67 | 84 | 129 | 135
AmBisome |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 132 | 156 | 275 | 277
AmBisome | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 15 | 13 | 40 | 25
AmBisome | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 63 | 69 | 129 | 135
AmBisome | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 54 | 74 | 107 | 117
Letairis |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 49 | 57 | 92 | 111
Letairis | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 49 | 57 | 92 | 111
Letairis | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Letairis | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 76 | 78 | 125 | 144
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 37 | 37 | 63 | 75
Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 26 | 31 | 41 | 51
Other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 13 | 10 | 22 | 18
Royalty, contract and other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 122 | 65 | 178 | 148
Royalty, contract and other revenues | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 85 | 20 | 112 | 40
Royalty, contract and other revenues | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 34 | 45 | 61 | 106
Royalty, contract and other revenues | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 2 | $ 0 | $ 5 | $ 2

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |